Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Cancer Specialists South
Fort Myers, Florida, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Florida Cancer Specialists North
St. Petersburg, Florida, United States
- Florida Cancer Specialists East
West Palm Beach, Florida, United States
- Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
- Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2014
- Primary completion
- 31 May 2016
- Completion
- 11 Dec 2017
- Last update posted
- 6 Mar 2019
- Registered enrollment
- 37
- Registry id
- NCT01487265
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.